NEW YORK (GenomeWeb) – Thermo Fisher Scientific and Biocept have signed a non-binding memorandum of understanding to collaborate commercially, Biocept said today.

The companies initially plan to validate Thermo Fisher's Oncomine next-generation sequencing liquid biopsy panels in Biocept's CLIA-certified laboratory.

Following that and other requirements, Thermo Fisher intends to designate Biocept as a Center of Excellence for oncology liquid biopsy initiatives and to pursue commercial opportunities with the company.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.